Epigenetic therapy using the histone deacetylase inhibitor for increasing therapeutic gain in oral cancer: Prevention of radiation-induced oral mucositis and inhibition of chemical-induced oral carcinogenesis

Carcinogenesis

Volumn 30, Issue 8, 2009, Pages 1387-1397

  Chung, Yih Lin ^a,b   Lee, Ming Yuan ^a,b   Pui, Newman N M ^c  

^a KOO FOUNDATION SUN YAT SEN CANCER CENTER   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c ASAN Laboratories Inc   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLBUTYRIC ACID DERIVATIVE; DIMETHYLBENZ[A]ANTHRACENE; HISTONE DEACETYLASE INHIBITOR; HISTONE H2AX; RAD51 PROTEIN; TUMOR NECROSIS FACTOR ALPHA; 4 PHENYLBUTYRIC ACID; 4-PHENYLBUTYRIC ACID; 7,12 DIMETHYLBENZ[A]ANTHRACENE; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; HISTONE; HISTONE DEACETYLASE; MESSENGER RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GENE THERAPY; CELL SURVIVAL; CHEMICAL CARCINOGENESIS; COMET ASSAY; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; DRUG EFFICACY; EPIGENETICS; GENE EXPRESSION; GENE LOCATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; MOUTH CANCER; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RADIATION EXPOSURE; RAT; REGULATORY MECHANISM; UPREGULATION; ACETYLATION; ANIMAL; APOPTOSIS; CELL CULTURE; CELL TRANSFORMATION; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; ENZYME IMMUNOASSAY; FIBROBLAST; GENE EXPRESSION REGULATION; GENETICS; HAMSTER; METABOLISM; MOUTH TUMOR; ORAL DRUG ADMINISTRATION; RADIATION DOSE; RADIATION INJURY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMATITIS; SYRIAN HAMSTER; WESTERN BLOTTING;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ACETYLATION; ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; CRICETINAE; DNA DAMAGE; DNA REPAIR; ENZYME INHIBITORS; FIBROBLASTS; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASES; HISTONES; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MESOCRICETUS; MOUTH NEOPLASMS; PHENYLBUTYRATES; RAD51 RECOMBINASE; RADIATION INJURIES; RADIATION TOLERANCE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STOMATITIS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 69449096433     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgp079     Document Type: Article

References (45)

1. Argiris, A. et al. (2008) Head and neck cancer. Lancet, 371, 1695-1709.
2. Rosenthal, D. I. et al. (2009) Strategies for managing radiation-induced mucositis in head and neck cancer. Semin. Radiat. Oncol., 19, 29-34.
3. Bairati, I. et al. (2005) Randomized trial of antioxidant vitamins to prevent acute adverse effects of radiation therapy in head and neck cancer patients. J. Clin. Oncol., 23, 5805-5813.
4. Khuri, F. R. et al. (2006) Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. J. Natl. Cancer Inst., 98, 441-450.
5. Shaw, R. (2006) The epigenetics of oral cancer. Int. J. Oral Maxillofac. Surg., 35, 101-108.
6. Choi, S. et al. (2008) Molecular pathogenesis of oral squamous cell carcinoma: Implications for therapy. J. Dent. Res., 87, 14-32.
7. Sonis, S. T. (2004) The pathobiology of mucositis. Nat. Rev. Cancer 4, 277-284.
8. Kobayashi, J. et al. (2008) Current topics in DNA double-strand break repair. J. Radiat. Res. (Tokyo), 49, 93-103.
9. Karagiannis, T. C. et al. (2004) Epigenetic changes activate widespread signals in response to double-strand breaks. Cancer Biol. Ther., 3, 617-623.
10. O'Hagan, H. M. et al. (2004) Double strand breaks can initiate gene silencing and SIRT1-dependent onset of DNA methylation in an exogenous promoter CpG island. PLoS Genet., 4, e1000155.
11. Conley, B. A. et al. (2006) Targeting epigenetic abnormalities with histone deacetylase inhibitors. Cancer, 107, 832-840.
12. Hill, R. P. et al. (2001) Normal tissue radiobiology: From the laboratory to the clinic. Int. J. Radiat. Oncol. Biol. Phys., 49, 353-365.
13. Chung, Y. L. et al. (2004) Antitumor histone deacetylase inhibitors suppress cutaneous radiation syndrome: Implications for increasing therapeutic gain in cancer radiotherapy. Mol. Cancer Ther. 3, 317-325.
14. Marks, P. A. et al. (2000) Histone deacetylase inhibitors: induction of differentiation or apoptosis of transformed cells. J. Natl. Cancer Inst., 92, 1210-1216.
15. Kazantsev, A. G. et al. (2008) Therapeutic application of histone deacetylase inhibitors for central nervous system disorders. Nat. Rev. Drug Discov., 7, 854-868.
16. Kang, H. L. et al. (2002) Life extension in Drosophila by feeding a drug. Proc. Natl Acad. Sci. USA, 99, 838-843.
17. Blanchard, F. et al. (2005) Histone deacetylase inhibitors: New drugs for the treatment of inflammatory diseases? Drug Discov. Today 10, 197-204.
18. Kemp, S. et al. (1998) Gene redundancy and pharmacological gene therapy: Implications for X-linked adrenoleukodystrophy. Nat. Med. 4, 1261-1268.
19. Iliopoulos, D. et al. (2007) Epigenetic regulation of leptin affects MMP-13 expression in osteoarthritic chondrocytes: Possible molecular target for osteoarthritis therapeutic intervention. Ann. Rheum. Dis., 66, 1616-1621.
20. Biade, S. et al. (2001) Chemical agents that promote chromatin compaction radiosensitize tumour cells. Int. J. Radiat. Biol., 77, 1033-1042.
21. Tabata, C. et al. (2006) All-trans-retinoic acid prevents radiation- or bleomycin-induced pulmonary fibrosis. Am. J. Respir. Crit. Care Med., 174, 1352-1360.
22. Yang, P. et al. (2008) Zyflamend reduces LTB4 formation and prevents oral carcinogenesis in a 7, 12-dimethylbenz[alpha]anthracene (DMBA)-induced hamster cheek pouch model. Carcinogenesis, 29 2182-2189.
23. Murphy, C. K. et al. (2008) Efficacy of superoxide dismutase mimetic M40403 in attenuating radiation-induced oral mucositis in hamsters. Clin. Cancer Res., 14, 4292-4297.
24. Singh, N. P. et al. (1988) A simple technique for quantitation of low levels of DNA damage in individual cells. Exp. Cell Res., 175, 184-191.
25. Buege, J. A. et al. (1978) Microsomal lipid peroxidation. Methods Enzymol., 52, 302-310.
26. Paull, T. T. et al. (2000) A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage. Curr. Biol., 10, 886-895.
27. Oberdoerffer, P. et al. (2008) SIRT1 redistribution on chromatin promotes genomic stability but alters gene expression during aging. Cell, 135, 907-918.
28. Binda, O. et al. (2008) SIRT1 negatively regulates HDAC1-dependent transcriptional repression by the RBP1 family of proteins. Oncogene 27, 3384-3392.
29. Volinia, S. et al. (2006) A microRNA expression signature of human solid tumors defines cancer gene targets. Proc. Natl Acad. Sci. USA 103, 2257-2261.
30. Richardson, C. (2005) RAD51, genomic stability, and tumorigenesis. Cancer Lett., 218, 127-139.
31. Sonis, S. T. (2004) A biological approach to mucositis. J. Support Oncol., 2, 21-32.
32. Stokman, M. A. et al. (2006) Preventive intervention possibilities in radiotherapy- and chemotherapy-induced oral mucositis: Results of metaanalyses. J. Dent. Res., 85, 690-700.
33. Spielberger, R. et al. (2004) Palifermin for oral mucositis after intensive therapy for hematologic cancers. N. Engl. J. Med., 351, 2590-2598.
34. Finch, P. W. et al. (2006) Keratinocyte growth factor expression and activity in cancer: Implications for use in patients with solid tumors. J. Natl. Cancer Inst., 98, 812-824.
35. Young, D. A. et al. (2005) Histone deacetylase inhibitors modulate metalloproteinase gene expression in chondrocytes and block cartilage resorption. Arthritis Res. Ther., 7, R503-R512.
36. Yamaguchi, K. et al. (2005) Histone deacetylase inhibitors suppress the induction of c-Jun and its target genes including COX-2. J. Biol. Chem., 280, 32569-32577.
37. Nakajima, T. (2006) Signaling cascades in radiation-induced apoptosis: roles of protein kinase C in the apoptosis regulation. Med. Sci. Monit., 12, RA220-RA224.
38. Kubota, K. et al. (2006) Suppressive effects of 4-phenylbutyrate on the aggregation of Pael receptors and endoplasmic reticulum stress. J. Neurochem., 97, 1259-1268.
39. Dokmanovic, M. et al. (2005) Prospects: Histone deacetylase inhibitors. J. Cell Biochem., 96, 293-304.
40. Brown, S. L. et al. (2008) Histone deacetylase inhibitors protect against and mitigate the lethality of total-body irradiation in mice. Radiat. Res., 169, 474-478.
41. Munshi, A. et al. (2005) Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity. Clin. Cancer Res., 11, 4912-4922.
42. Insinga, A. et al. (2005) Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat. Med., 11, 71-76.
43. Nebbioso, A. et al. (2005) Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat. Med., 11, 77-84.
44. Papeleu, P. et al. (2005) Differential effects of histone deacetylase inhibitors in tumor and normal cells-what is the toxicological relevance? Crit. Rev. Toxicol., 35, 363-378.
45. Van Lint, C. et al. (1996) The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gene Expr., 5, 245-253.